poba
Seres Therapeutics (NASDAQ:MCRB) and partner Nestle Health Science (OTCPK:NSRGY) announced the the US launch of their new treatment Vowst for the prevention of recurrence of C. difficile infection in adults who have already been treated with antibiotics for a recurrence of the illness.
The product, which contains fecal microbiota spores, is intended to prevent recurrence of the infection and is not a treatment for the infection itself, according to the companies.
More on Seres:
Seres receives $125M milestone payment for FDA Approval of Vowst for C. difficile Infection
Seres adds 11% on FDA nod microbiome therapy